Registry for patients with myelodysplastic syndrome in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a network of regional registries in Italy to collect and analyze epidemiological data from adult patients newly diagnosed with myelodysplastic syndrome (MDS). By utilizing a standardized electronic case report form, the study will aggregate anonymous data from various regions, facilitating a comprehensive understanding of MDS across the country. The collected data will also be compared with international registries to enhance the knowledge base surrounding this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* New diagnosis of MDS

Exclusion Criteria:

* Patient who refuse the signature of informed consent

Where it's running

• Ematologia, AO SS. Antonio e Biagio
  Alessandria, Al, Italy Recruiting
• Clinica di Ematologia, AOU Ospedale di Torrette
  Ancona, An, Italy Recruiting
• U.O. Clinica Medicina Interna, IRCCS San Martino IST
  Genova, Ge, Italy Recruiting
• Struttura Cattedra di Ematologia e CTMO, AOU di Parma
  Parma, Pr, Italy Recruiting
• Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata
  Rionero in Vulture, Pz, Italy Recruiting
• FPO - IRCCS di Candiolo
  Candiolo, Torino, Italy Recruiting

Study contacts

• Study coordinator: Valeria Santini, Prof.
• Email: segreteriafismonlus@ospedale.al.it
• Phone: 013120

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients with myeloproliferative neoplasms

  This study is creating a database to gather information from people with myeloproliferative neoplasms to help improve treatments and outcomes for these rare blood cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT02760238

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Access and distribution of unlicensed cryopreserved cord blood units

  This study is testing how well unlicensed frozen cord blood units work for helping both kids and adults with blood cancers recover after a transplant.

  Recruiting at 113 sites Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 141 other locations · NCT01351545

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Ruxolitinib given before, during, and after donor stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap

  This phase II test tries whether giving ruxolitinib before, during, and after an allogeneic stem cell transplant helps older adults with myelofibrosis or MDS/MPN overlap have better transplant outcomes and fewer complications like graft-versus-host disease.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07228624

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.